Logo image of SNPX

TRADR 2X LONG SNPS DAILY ETF (SNPX) Stock Price, Forecast & Analysis

USA - NYSE Arca - NYSEARCA:SNPX - US46092D3439 - ETF

34.9685 USD
+0.35 (+1.01%)
Last: 12/26/2025, 8:16:30 PM
30.94 USD
-4.03 (-11.52%)
After Hours: 12/12/2025, 8:04:00 PM
Buy % Consensus

83

ChartMill assigns a Buy % Consensus number of 83% to SNPX. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 14.28. This target is -59.16% below the current price.
SNPX was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about SNPX.
In the previous month the buy percentage consensus was at a similar level.
SNPX was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

SNPX Historical Analyst RatingsSNPX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -26 -24 -22 -20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6

Price Target & Forecast

Price Low Median Mean High 34.9714.1414.2814.2814.70 - -59.56% -59.16% -59.16% -57.96%

Related screens

SNPX Current Analyst RatingSNPX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2024-07-11 Maxim Group Upgrade Hold -> Buy
2022-12-19 Maxim Group Downgrade Buy -> Hold
2022-04-12 Maxim Group Initiate Buy

TRADR 2X LONG SNPS DAILY ETF / SNPX FAQ

What does TRADR 2X LONG SNPS DAILY ETF do?

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.


What is the current price of SNPX stock?

The current stock price of SNPX is 34.9685 USD. The price increased by 1.01% in the last trading session.


What is the ChartMill technical and fundamental rating of SNPX stock?

SNPX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is SNPX stock listed?

SNPX stock is listed on the NYSE Arca exchange.